

February 11, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

BSE Limited
Pheroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
(ii) SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sub: Investors Presentation- Quarter III ended on December 31, 2025 – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and in continuation to our earlier intimation dated February 06, 2026 regarding the Analysts/Investors Earning Call scheduled to be held on February 12, 2026 at 04:30 P.M. (IST), please find enclosed the Investors Presentation, inter-alia, including the financial performance of the Company for the Quarter-III ended on December 31, 2025.

The Investor Presentation is also made available on the website of the Company.

You are requested to take the above intimation on record.

Thanking You,
For Orchid Pharma Limited

**Manish Dhanuka
Managing Director
DIN- 00238798**

Encl. as above

Orchid Pharma Limited

Financials Q3 & 9M FY-26


- All results in standalone basis.
- These are approx. figures, for exact nos. please refer financials for details

Financial Performance




| (Amt. in Cr.) | Q3-26 | Q3-25 | Change % | 9M-26 | 9M-25 | % Change |
|--------------------------|-------|-------|----------|-------|-------|----------|
| Sales | 207 | 217 | -5% | 574 | 684 | -16% |
| Other Income | 11 | 10 | +10% | 42 | 26 | +62% |
| COGS | 143 | 124 | | 374 | 406 | |
| Employee Exp | 23 | 22 | +5% | 69 | 64 | +8% |
| Other Exp | 38 | 44 | -14% | 114 | 125 | -9% |
| EBITDA* | 13 | 37 | -65% | 58 | 115 | -50% |
| % to Sales | 6% | 17% | | 10% | 17% | |
| Interest | 3 | 4 | -25% | 10 | 11 | -9% |
| Depreciation | 9 | 9 | | 26 | 26 | |
| Exceptional Items | 7 | 0 | | 7 | 0 | |
| PBT & PAT | -6 | 24 | | 15 | 78 | |


Turnover (Amt. in Cr.)




EBIDTA & PBT as % to Sales Q3



P&L Analysis – Gross Margin % to Sales Q3



P&L Analysis – Exp. % to Sales Q3



Thank You